Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04738812
Other study ID # ANRS 12424 DATURA
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date April 21, 2022
Est. completion date March 2025

Study information

Verified date September 2022
Source ANRS, Emerging Infectious Diseases
Contact BLANC François-Xavier, MD, PhD
Phone +33 240 165 545
Email xavier.blanc@chu-nantes.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

DATURA trial is a phase III, multicenter, two-arm, open-label, randomized superiority trial to compare the efficacy and the safety of an intensified tuberculosis (TB) regimen versus standard TB treatment in HIV-infected adults and adolescents hospitalized for TB with CD4 ≤ 100 cells/μL over 48 weeks: - Intensified TB treatment regimen: increased doses of rifampicin and isoniazid together with standard-dose of pyrazinamide and ethambutol for 8 weeks in addition to prednisone for 6 weeks and albendazole for 3 days - WHO standard TB treatment regimen. The continuation phase of TB treatment will be identical in the two arms: 4 months of rifampicin and isoniazid at standard doses.


Description:

Settings: 4 African (Cameroon, Guinea, Uganda, Zambia) and 2 South-East Asian (Cambodia, Vietnam) countries. Sample size : 1330 patients (665 in each arm). Follow-up : 48 weeks after entry in the trial (TB treatment initiation). All participants will initiate antiretroviral therapy (ART) 2 weeks after starting TB treatment. In each country, the chosen ART regimen will be the same in both arms. According to the first-line regimen recommended in each country, the ART combination will be TDF/3TC/EFV 600 mg, or TDF/3TC + double-dose DTG. The primary objective is to estimate the impact of an intensified initial phase of TB treatment on mortality at 48 weeks among HIV-infected adults and adolescents hospitalized for TB with CD4 ≤ 100 cells/μL in comparison with standard TB treatment. The secondary objectives are to estimate the impact of an intensified initial phase of TB treatment, in comparison with the standard TB regimen, on: - Mortality at weeks 8 and 24 - Adverse events, including - All grade 3 and 4 events - Selected grade 2 events of interest - Drug-related adverse events - AIDS-defining illnesses - Paradoxical TB-associated immune reconstitution inflammatory syndrome (IRIS) - TB treatment success - TB recurrence - ART response in terms of virological success and immunological response - Adherence to TB treatment and ART - Peak plasma concentrations of rifampicin and isoniazid (and its N-acetyl-metabolite) at day 3, day 7 and week 2 - Plasma concentrations of efavirenz and dolutegravir at week 4 (i.e. 2 weeks after the onset of ART). A pharmacokinetic sub-study of rifampicin and isoniazid will be carried out in 72 voluntary patients (6 patients/arm/country) at the second week of the main study.


Recruitment information / eligibility

Status Recruiting
Enrollment 1330
Est. completion date March 2025
Est. primary completion date March 2025
Accepts healthy volunteers No
Gender All
Age group 15 Years and older
Eligibility INCLUSION CRITERIA - Patient (and legally designed representative of minor patient) able to correctly understand the trial and to sign the informed consent - Aged = 15 years - Confirmed HIV-1 infection as documented at any time prior to trial entry per national HIV testing procedures - CD4 count = 100 cells/µL - Hospitalized for a newly diagnosed TB, defined by: - Any positive Xpert® MTB/RIF specimen (sputum, urine, pus, other), - Or a positive urine lipoarabinomannan (LAM) test, - Or an abnormal chest X-ray compatible with active TB EXCLUSION CRITERA - Initiation of TB drugs for more than 3 days - History of TB treatment during the last 6 months - Central neurological symptoms, including but not restrictive to TB meningitis - Suspected TB pericarditis - Documented Mycobacterium tuberculosis strain resistant to rifampicin using rapid molecular testing (Xpert® MTB/RIF) - Any concomitant medication or known hypersensitivity contraindicating any component of the TB treatment - HIV-2 co-infection - History of ART, unless if stopped for more than 1 year - Current treatment with ART for more than 1 week - Any contraindication to efavirenz and dolutegravir - Severe associated diseases requiring specific treatment (including all specific AIDS defining illnesses other than TB and any severe sepsis) - Impaired hepatic function with ALT (SGPT) > 5 times the upper limit of normal (ULN) value - Creatinine clearance < 50 mL/min (according to the Cockcroft-Gault formula) - Pregnancy or breastfeeding

Study Design


Intervention

Drug:
Intensified TB treatment (initial phase)
8 weeks of RHEZ with high dose of rifampicin (R) and isoniazid (H). Fixed dose combination (FDC) of RHZE with the addition of FDC of RH and single caps of R. 6 weeks of prednisone with tapering doses. 3 days of albendazole 400 mg.
WHO standard TB treatment (initial phase)
8 weeks of RHEZ with FDC.

Locations

Country Name City State
Cambodia National Center for HIV/AIDS, Dermatology and STD (NCHADS) Phnom Penh
Cameroon Jamot Hospital Yaoundé
Guinea Ignace Deen Hospital Conakry
Uganda Mbarara Regional Referral hospital Mbarara
Vietnam Pham Ngoc Thach Hospital Ho Chi Minh City
Zambia University Teaching Hospital Lusaka

Sponsors (3)

Lead Sponsor Collaborator
ANRS, Emerging Infectious Diseases European and Developing Countries Clinical Trials Partnership (EDCTP), European Union

Countries where clinical trial is conducted

Cambodia,  Cameroon,  Guinea,  Uganda,  Vietnam,  Zambia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of all causes death Number of deaths between the inclusion visit and week 48, divided by the total person-years of follow-up until week 48 Up to 48 weeks
Secondary Rate of all causes death Death for any cause at week 8 will be calculated as the number of deaths between the inclusion visit and week 24, divided by the total person-years of follow-up during the same period Up to 8 weeks
Secondary Rate of all causes death Death for any cause at week 24 will be calculated as the number of deaths between the inclusion visit and week 24, divided by the total person-years of follow-up during the same period Up to 24 weeks
Secondary Rate of adverse events Number of serious adverse events, all grade 3-4 adverse events (using the DAIDS tables), and any grade 2 adverse events of interest (e.g., hepatotoxicity, rash, peripheral neuropathy, thrombocytopenia, neuropsychiatric disorders), between the inclusion visit and week 48, divided by the total person-years of follow-up during that period Up to 48 weeks
Secondary Rate of AIDS-defining illnesses Number of AIDS-defining illnesses according to the WHO clinical staging table Up to 48 weeks
Secondary Rate of paradoxical TB-associated IRIS Number of paradoxical TB-associated IRIS according to the definition of the international network for the study of HIV-associated (INSHI) consensus case definition Up to 14 weeks
Secondary Rate of TB treatment success The percentage of patients with TB success will be calculated as the number of patients who are cured or who have completed TB treatment, as defined by WHO, divided by the total number of randomized patients Up to 24 weeks
Secondary Rate of TB recurrence The number of patients with TB recurrence divided by the total number of randomized patients with TB treatment success at week 24 Up to 48 weeks
Secondary Rate of virological success The percentage will be calculated as the number of patients with HIV RNA <50 copies/mL divided by the total number of randomized patients. Week 24
Secondary Rate of virological success The percentage will be calculated as the number of patients with HIV RNA <50 copies/mL divided by the total number of randomized patients. Week 48
Secondary Adherence to TB and ART treatment The proportion of days with perfect adherence divided by the total number of days of treatment up to 24 weeks
Secondary Immunological response The mean CD4 cell count gain (with 95% confidence interval) will be calculated as the difference of CD4 cell count between pre-inclusion and week 48 Up to 48 weeks
Secondary Plasma concentrations of rifampicin and isoniazid Determined 2 hours after the TB drugs intake at day 3, day 7 and week 2 in a subset of 20 patients per arm per country Up to 2 weeks
Secondary Plasma concentrations of efavirenz and dolutegravir Determined 12 hours after the drugs intake at week 4 (i.e. 2 weeks after the onset of ART) in a subset of 60 patients per arm for efavirenz and 60 patients per arm for dolutegravir Week 4
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2